09:10 AM EDT, 09/24/2025 (MT Newswires) -- Hoth Therapeutics ( HOTH ) said Wednesday that it has expanded its intellectual property portfolio for HT-001, its lead topical drug candidate, by filing multiple US provisional patent applications.

The company said the new filings cover additional dermatological uses, broadening both the clinical and commercial potential of HT-001.

Hoth Therapeutics ( HOTH ) said one provisional patent application for HT-001 pertains to the treatment of skin conditions associated with MENIN inhibitor therapy. MENIN inhibitors are an emerging class of targeted cancer drugs whose use is limited by significant skin side effects that can limit treatment tolerability, the company said.

HT-001's formulation is designed to relieve the side effects without disrupting cancer therapy, potentially allowing patients to stay on treatment longer and improve outcomes, the company said.

Shares were up 2.4% in recent premarket activity.